| Trial ID: | L0747 |
| Source ID: | NCT01636466
|
| Associated Drug: |
Everolimus
|
| Title: |
The Everolimus-Transplant Exit Strategy Trial (E-TEST)
|
| Acronym: |
E-TEST
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01636466/results
|
| Conditions: |
Kidney Failure, Chronic
|
| Interventions: |
DRUG: Everolimus
|
| Outcome Measures: |
Primary: Mean Fluorescence Index (MFI) of Donor Specific Alloantibodies (DSA), Development of new donor-specific alloantibody as determined by solid phase bead array (Luminex) technology defining MFIs for fine specificity at Class I and Class II antigens (human leukocyte antigens (HLA) - A, B, C, DR, DP, and DQ) with an MFI \>5000 defined as positive, 36 months | Secondary: Incidence of Return to Dialysis Dependence, 36 months
|
| Sponsor/Collaborators: |
Sponsor: Ashtar Chami | Collaborators: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
1
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-06
|
| Completion Date: |
2014-05
|
| Results First Posted: |
2015-06-08
|
| Last Update Posted: |
2018-02-05
|
| Locations: |
Emory University, Atlanta, Georgia, 30322, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01636466
|
